# Nanomedicine Meets Immunotherapy: Transforming Chimeric Antigen Receptor T Cell Treatment for Solid Tumors

## TL;DR

This review explores how nanomedicine can improve CAR T cell therapy for solid tumors by addressing challenges like poor T cell infiltration and immunosuppressive environments.

## Contribution

The paper highlights recent nanotechnology-based strategies to enhance CAR T cell therapy's effectiveness in solid tumors.

## Key findings

- Nanotechnology can improve tumor targeting and T cell infiltration in solid tumors.
- Nanomaterials can help remodel the immunosuppressive tumor microenvironment.
- Integration of nanomaterials into CAR T cell platforms may lead to more effective cancer therapies.

## Abstract

The emergence of effective immunotherapies has drastically revolutionized clinical management of many cancer types. Among them, chimeric antigen receptor (CAR)‐T cell therapy (CTT), as a groundbreaking approach, has been considered as a “living drug,” displaying unprecedented clinical outcomes with hematological malignancies, including B cell leukemia and lymphomas, and multiple myeloma. Despite the high remission rates and improved survival achieved with hematological cancers, the effectiveness of CTT in solid tumors remains largely unsatisfactory. The efficacy of CTT in solid tumors is significantly challenged by multiple factors, including tumor‐antigen heterogeneity, limited T cell trafficking and infiltration, a highly immunosuppressive tumor microenvironment, and the risk of severe adverse effects. Accumulating evidence highlights the potential of nanotechnology to address these obstacles, paving the way for more effective CTT against solid tumors. Thus, this review explores to highlight the evolution and challenges of CTT in solid tumors, while summarizing the up‐to‐date advances of nanotechnology‐enabled CTT with the intention towards the formulation of a more cohesive, personalized, and effective cancer therapy in the future.

This review highlights recent advances in nanomedicine that enhance chimeric antigen receptor (CAR) T cell therapy against solid tumors. It discusses key barriers to CAR T cell efficacy and outlines nanotechnology‐based strategies to improve tumor targeting, remodel the immunosuppressive microenvironment, and integrate nanomaterials into CAR T cell platforms for improved therapeutic outcomes.© 2026 WILEY‐VCH GmbH